-
公开(公告)号：US20190337910A1
公开(公告)日：2019-11-07
申请号：US16087382
申请日：2017-03-20
发明人： BRENDAN M. CROWLEY , BRIAN T. CAMPBELL , JOSEPH L. DUFFY , THOMAS J. GRESHOCK , DEODIAL G. GUIADEEN , ANDREW JOHN HARVEY , BELINDA C. HUFF , KENNETH J. LEAVITT , VANESSA L. RADA , JOHN M. SANDERS , WILLIAM D. SHIPE , LINDA M. SUEN , IAN M. BELL
IPC分类号： C07D285/12 , C07D231/12 , C07D233/64 , C07D249/06 , C07D249/08 , C07D261/08 , C07D263/32 , C07D271/06 , C07D277/26 , C07D285/08 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/04
摘要： The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
-
公开(公告)号：US20190119223A1
公开(公告)日：2019-04-25
申请号：US16094910
申请日：2017-05-11
IPC分类号： C07D257/04 , C07C323/63 , C07D403/12 , C07D401/12 , C07D413/12 , C07D405/12 , C07D417/12 , C07D285/08 , C07C323/42 , C07C323/45 , C07F9/6524 , C07D401/04 , C07D401/10 , C07D249/06 , C07D249/08 , C07D271/06
CPC分类号： C07D257/04 , C07C323/42 , C07C323/45 , C07C323/63 , C07D249/06 , C07D249/08 , C07D271/06 , C07D285/08 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07F9/6524
摘要： Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
-
公开(公告)号：US10266505B2
公开(公告)日：2019-04-23
申请号：US16012536
申请日：2018-06-19
IPC分类号： A61K31/4245 , C07D285/08 , C07D271/10 , C07D271/107 , A61K31/433 , A61K45/06 , A61K31/167 , C07D271/113
摘要： The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.
-
公开(公告)号：US10029997B2
公开(公告)日：2018-07-24
申请号：US15317559
申请日：2015-06-12
IPC分类号： C07D271/10 , C07D271/107 , C07D271/113 , C07D285/08 , A61K31/433 , A61K45/06 , A61K31/167 , A61K31/4245
摘要： The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.
-
公开(公告)号：US10012777B2
公开(公告)日：2018-07-03
申请号：US14758750
申请日：2014-01-09
申请人： KONICA MINOLTA, INC.
发明人： Hiroyoshi Kiuchi , Takatugu Suzuki , Kiyoshi Fukusaka , Rie Fujisawa , Hiroshi Kita , Issei Nakahara
IPC分类号： G02B5/30 , C08K5/3472 , C07D249/04 , H01L51/00 , G02F1/13363 , C07D403/00 , C08J5/18 , C08K5/34 , C08L1/08 , C08L101/14 , C07D403/12 , C07D401/04 , C07D403/10 , C07D403/14 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D249/08 , C07D249/10 , C07D249/12 , C07D249/14 , C07D271/10 , C07D207/32 , C07D285/08 , C08L1/10 , C08L1/12 , C08L1/28 , G02F1/1335
CPC分类号： G02B5/3083 , C07D207/32 , C07D249/04 , C07D249/08 , C07D249/10 , C07D249/12 , C07D249/14 , C07D271/10 , C07D285/08 , C07D401/04 , C07D403/00 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/04 , C07D417/04 , C08J5/18 , C08J2301/08 , C08K5/34 , C08K5/3472 , C08L1/08 , C08L1/10 , C08L1/12 , C08L1/28 , C08L101/14 , G02B5/30 , G02B5/305 , G02F1/13363 , G02F1/133634 , G02F2001/133541 , G02F2001/133638 , H01L51/0034 , H01L51/0067
摘要： The present invention provides a resin composition capable of forming a film exhibiting a small humidity-dependent variation in optical values; a triazole compound to be incorporated into the resin composition; an optical film and an optical lens, each of which is prepared from the resin composition and exhibits a small humidity-dependent variation in optical values; and a polarizing plate, a circularly polarizing plate, and an image display device, each of which includes the optical film and exhibits excellent moisture resistance. The resin composition of the present invention contains a resin and a compound having a 5-membered or 6-membered aromatic hydrocarbon or heterocyclic ring, wherein the resin is a hygroscopic resin, the compound has at least three specific aromatic rings having a specific NICS value, and the specific aromatic rings are bonded to one another via a single bond or one or two atoms.
-
公开(公告)号：US20180162868A1
公开(公告)日：2018-06-14
申请号：US15600612
申请日：2017-05-19
发明人： Jean-Christophe Andrez , David Earl Bogucki , Kristen Nicole Burford , Sultan Chowdhury , Charles Jay Cohen , Shannon Marie Decker , Christoph Martin Dehnhardt , Robert Joseph Devita , James Roy Empfield , Thilo Focken , Michael Edward Grimwood , Syed Abid Hasan , Qi Jia , James Philip Johnson, JR. , Michael Scott Wilson , Alla Yurevna Zenova
IPC分类号： C07D491/107 , C07D277/52 , C07D417/12 , C07D213/76 , C07D285/08 , C07D401/12 , C07D403/12 , C07D275/03 , C07D239/69 , C07D261/16 , C07D413/12 , C07D263/50 , C07D487/10
摘要： This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
-
公开(公告)号：US20180162853A1
公开(公告)日：2018-06-14
申请号：US15882386
申请日：2018-01-29
发明人： Shigemitsu MATSUMOTO , Yasushi HATTORI , Masashi TOYOFUKU , Shinji MORIMOTO , Masaki DAINI , Takuto KOJIMA , Tomohiro KAKU , Mitsuhiro ITO
IPC分类号： C07D417/14 , C07D333/38 , C07D413/14 , C07D407/12 , C07D307/79 , C07D409/12 , C07D417/12 , C07D307/81 , C07D413/12 , C07D409/14 , C07D231/12 , C07D277/56 , C07D285/135 , C07D285/08 , C07D333/40 , C07D231/14 , C07D213/82
CPC分类号： C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号：US09920042B2
公开(公告)日：2018-03-20
申请号：US14430604
申请日：2013-09-27
发明人： Nicolas Willand , Benoit Deprez , Alain Baulard , Priscille Brodin , Olivier Sperando , Vincent Villeret , Baptiste Villemagne
IPC分类号： C07D277/26 , C07D277/30 , C07D417/04 , C07D213/81 , C07D249/06 , C07D249/08 , C07D271/06 , C07D277/56 , C07D277/66 , C07D285/08 , C07D285/12 , C07D291/04 , C07C255/57 , C07C311/37 , C07C247/18 , A61K31/155 , A61K31/175 , A61K31/4192 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/44 , A61K31/4436 , A61K31/277 , A61K31/4439 , A61K45/06 , C07C255/60 , C07D263/32 , C07D277/28
CPC分类号： C07D417/04 , A61K31/155 , A61K31/175 , A61K31/277 , A61K31/4192 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K45/06 , C07C247/18 , C07C255/57 , C07C255/60 , C07C311/37 , C07D213/81 , C07D249/06 , C07D249/08 , C07D263/32 , C07D271/06 , C07D277/26 , C07D277/28 , C07D277/30 , C07D277/56 , C07D277/66 , C07D285/08 , C07D285/12 , C07D291/04 , A61K2300/00
摘要： The present invention concerns compounds of general formula (I): in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or substituted by fluorine, the unsubstituted or substituted cyclic, cyano, azido, alkoxy and phenyl groups; and R is chosen from the azido, cyano, alkinyl and 2-benzothiazolyl groups and an optionally substituted aromatic heterocycle with five vertices; and the use thereof in the treatment of bacterial and mycobacterial infections such as, for example, tuberculosis, leprosy and atypical mycobacterial infections. The present invention also concerns pharmaceutical compositions comprising, as the active ingredient, at least one of the abovementioned compounds and optionally an antibiotic activatable via the EthA pathway.
-
公开(公告)号：US09828351B2
公开(公告)日：2017-11-28
申请号：US15321693
申请日：2015-06-26
申请人： MONASH UNIVERSITY , UNIVERSITY OF SOUTH AUSTRALIA , CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED
发明人： Bernard Luke Flynn , Luigi Aurelio , Carmen Vittoria Scullino , Bing Hui Wang , Stuart Maxwell Pitson , Melissa Rose Pitman
IPC分类号： C07D271/113 , C07D285/08 , C07D419/12 , C07D285/135 , C07D271/07 , C07D277/56 , C07D271/10 , C07D413/12 , C07D413/10 , C07D271/107
CPC分类号： C07D285/08 , C07D271/06 , C07D271/07 , C07D271/10 , C07D271/107 , C07D271/113 , C07D277/56 , C07D285/135 , C07D413/10 , C07D413/12 , C07D419/12
摘要： The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosure further relates to the use of such compounds as research tools, use in therapy, to compositions and agents comprising said compounds, and to methods of treatment using said compounds.
-
公开(公告)号：US20170275260A1
公开(公告)日：2017-09-28
申请号：US15463336
申请日：2017-03-20
发明人： BRENDAN M. CROWLEY , BRIAN T. CAMPBELL , JOSEPH L. DUFFY , THOMAS J. GRESHOCK , DEODIAL G. GUIADEEN , ANDREW JOHN HARVEY , BELINDA C. HUFF , KENNETH J. LEAVITT , VANESSA L. RADA , JOHN M. SANDERS , WILLIAM D. SHIPE , LINDA M. SUEN , IAN M. BELL
IPC分类号： C07D285/12 , A61K31/4245 , A61K31/433 , C07D271/107 , C07D263/32 , A61K31/421 , C07D261/08 , A61K31/42 , C07D249/04 , A61K31/4192 , C07D231/12 , A61K31/415 , C07D277/26 , A61K31/426 , C07D285/08 , C07D271/06
CPC分类号： C07D285/12 , A61K31/415 , A61K31/4192 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/433 , C07D231/12 , C07D233/64 , C07D249/04 , C07D249/06 , C07D249/08 , C07D261/08 , C07D263/32 , C07D271/06 , C07D271/10 , C07D271/107 , C07D277/26 , C07D285/08 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/04 , C07D495/04
摘要： The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
-
-
-
-
-
-
-
-
-
搜索结果
770 条记录 (耗时 0.059 秒)
